Vaxart at Euro Congress of Clinical Microbiology & Infectious Diseases

Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist at Vaxart, will present preclinical data in a poster presentation at the 29^th European Congress of Clinical Microbiology and Infectious Diseases showing that Vaxart’s oral quadrivalent influenza vaccine conferred 100% protection against a lethal H5N1 avian influenza challenge in ferrets.

Details of the presentation are as follows:

Poster Title: Oral adenovirus-based quadrivalent influenza vaccine protects ferrets from lethal challenge with a pandemic H5N1 influenza virus (Vietnam H5N1)
Poster Number: P0386
Date & Time: Saturday, April 13, 2019 at 3:30 – 4:30 PM GMT
Authors: Roberto Mateo, et al.
Session: Vaccination: from bench to practice

The Vaxart oral quadrivalent influenza vaccine was compared head-to-head with placebo and quadrivalent injectable Fluzone^® in ferrets that received a lethal challenge of H5N1 avian influenza 28 days post immunization. The Vaxart quadrivalent vaccine was matched with the quadrivalent Fluzone, covering the same four influenza strains. Neither the Vaxart quadrivalent vaccine nor the quadrivalent Fluzone covered H5N1 strains. Both vaccines were administered at an equivalent dose and animals were followed for 15 days after challenge. Ferrets in the placebo group had a 25% survival rate while 62% of the animals in the Fluzone group survived. In contrast, 100% of the animals receiving the oral Vaxart vaccine survived.

https://www.biospace.com/article/releases/vaxart-to-present-at-the-29th-european-congress-of-clinical-microbiology-and-amp-infectious-diseases/